Search results for "Survival"

showing 10 items of 3291 documents

The prognostic value of four interleukin-1 gene polymorphisms in caucasian women with breast cancer – a multicenter study

2009

Abstract Background The proinflammatory cytokine interleukin-1 (IL-1) is known to play an important role in the carcinogenesis of breast cancer. Although IL-1 gene polymorphisms were reported to be associated with increased risk of breast cancer, their influence on survival of Caucasian breast cancer patients remains to be shown. Methods We studied the influence of four common gene polymorphisms (IL1A -889C/T, IL1B -511C/T, IL1B +3953E1/E2, and IL1RN long/2) of the IL-1 family on survival in 262 Caucasian patients with breast cancer by univariate and multivariate survival analysis. The combined effect of the four gene polymorphisms on overall survival was studied by haplotype analysis. Resu…

Oncologymedicine.medical_specialtyCancer ResearchBreast Neoplasmsmedicine.disease_causelcsh:RC254-282Disease-Free SurvivalWhite PeopleBreast cancerInternal medicineGeneticsMedicineHumansAlleleAllelesPolymorphism Geneticbusiness.industryHaplotypeCancerOdds ratioMiddle Agedmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensInterleukin 1 Receptor Antagonist ProteinIL1AOncologyImmunologyFemaleGene polymorphismbusinessCarcinogenesisInterleukin-1Research ArticleBMC Cancer
researchProduct

Detection methods predict differences in biology and survival in breast cancer patients

2012

Abstract Background The aim of this study was to measure the biological characteristics involved in tumorigenesis and the progression of breast cancer in symptomatic and screen-detected carcinomas to identify possible differences. Methods For this purpose, we evaluated clinical-pathological parameters and proliferative and apoptotic activities in a series of 130 symptomatic and 161 screen-detected tumors. Results After adjustment for the smaller size of the screen-detected carcinomas compared with symptomatic cancers, those detected in the screening program presented longer disease-free survival (RR = 0.43, CI = 0.19-0.96) and had high estrogen and progesterone receptor concentrations more …

Oncologymedicine.medical_specialtyCancer ResearchSurvivalProliferationBreast NeoplasmsApoptosisKaplan-Meier Estimatemedicine.disease_causelcsh:RC254-282Breast cancerBreast cancerSurgical oncologyInternal medicineDetection methodsmedicineGeneticsHumansMammographyEarly Detection of CancerProportional Hazards Modelsmedicine.diagnostic_testbusiness.industryProportional hazards modelDisease progressionCase-control studyMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosismedicine.diseaseImmunohistochemistryOncologyCase-Control StudiesDisease ProgressionImmunohistochemistryFemalebusinessCarcinogenesisMammographyResearch Article
researchProduct

TACE versus TAE as therapy for hepatocellular carcinoma

2008

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear. TACE may not be better than transarterial embolization (TAE). HCC is very chemoresistant, thus embolization may be more important than chemotherapy. Lipiodol cannot be considered as an embolic agent and there are no data to show that it can release chemotherapeutic agents slowly. It can mask residual vascularity on CT imaging and its use is not recommended. Both TACE and TAE result in hypoxia, which stimulates angiogenesis, promoting tumor growth; thus combination of TACE with antiangiogenic agen…

Oncologymedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomaRadiofrequency ablationmedicine.medical_treatmentAntineoplastic Agentslaw.inventionRecurrencelawInternal medicineCarcinomamedicineHumansPharmacology (medical)EmbolizationChemoembolization TherapeuticSurvival rateChemotherapybusiness.industryLiver Neoplasmsmedicine.diseaseSurvival RateTransplantationOncologyHepatocellular carcinomaLipiodolRadiologybusinessmedicine.drugExpert Review of Anticancer Therapy
researchProduct

Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence

2021

Direct-acting antivirals (DAAs) revolutionized the treatment of chronic HCV-related disease achieving high rates of sustained virological response (SVR), even in advanced cirrhosis, with modest contraindications and a low rate of adverse events. However, the risk of hepatocellular carcinoma (HCC) persists due to the underlying chronic liver disease, both in patients with and without history of HCC. Although some initial studies reported a presumptive high risk of HCC development after DAA therapy, more recent observational studies denied this hypothesis. The residual risk for HCC occurrence after HCV eradication seems being progressively reduced with time after SVR. Data on recurrence of HC…

Oncologymedicine.medical_specialtyCarcinoma HepatocellularSustained Virologic ResponseSurvivalHepatocellular carcinomaHepatitis C virusSpecialties of internal medicineDiseaseDirect-acting antiviralsDirect-acting antiviralmedicine.disease_causeChronic liver diseaseAntiviral AgentsRecurrenceInternal medicineCarcinomaHumansMedicineAdverse effectRetrospective StudiesHepatologyHepatitis C virusbusiness.industryLiver NeoplasmsGeneral MedicineHepatitis C Chronicmedicine.diseasedigestive system diseasesResidual riskRC581-951Hepatocellular carcinomaObservational studyHepatitis C virubusinessAnnals of Hepatology
researchProduct

Are radiological endpoints surrogate outcomes of overall survival in hepatocellular carcinoma treated with transarterial chemoembolization?

2021

Background& Aims: Time to progression (TTP) and progression-free survival (PFS) are commonly used as surrogate endpoints in oncology trials. We aimed to assess the surrogacy relationship of TTP and PFS with overall survival (OS) in studies of transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (u-HCC) by innovative methods. Methods: A search of databases for studies of TACE for u-HCC reporting both OS and TTP or PFS was performed. Individual patient data were extracted from TTP/PFS and OS Kaplan-Meier curves of TACE arms. Pooled median TTP and OS were obtained from random-effect model. The surrogate relationships of hazard ratios (HRs) and median TTP for OS …

Oncologymedicine.medical_specialtyCarcinoma Hepatocellularoverall survivaltransarterial chemoembolizationtime to progressionSystemic therapy03 medical and health sciences0302 clinical medicineInternal medicinemedicineOverall survivalsurrogate endpointHumansProgression-free survivalChemoembolization TherapeuticneoplasmsNeoplasm StagingHepatologybusiness.industrySurrogate endpointLiver NeoplasmsHazard ratiohepatocellular carcinomamedicine.diseaseCombined Modality TherapyConfidence intervalTreatment Outcomesurrogate endpoints030220 oncology & carcinogenesisHepatocellular carcinomaRadiological weaponDisease Progression030211 gastroenterology & hepatologyRadiologybusinessprogression-free survival
researchProduct

A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma

2017

Background & Aims: Determining risk for recurrence or survival after curative resection or ablation in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is important for stratifying patients according to expected outcomes in future studies of adjuvant therapy in the era of direct-acting antivirals (DAAs). The aims of this meta-analysis were to estimate the recurrence and survival probabilities of HCV-related early HCC following complete response after potentially curative treatment and to identify predictors of recurrence and survival. Methods: Studies reporting time-dependent outcomes (HCC recurrence or death) after potentially curative treatment of HCV-relat…

Oncologymedicine.medical_specialtyCarcinoma HepatocellularrecurrenceHepatitis C virusmedicine.medical_treatmentmedicine.disease_causesurvivallaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdjuvant therapyhepatocellular carcinoma; prognosis; recurrences; survivalHumansSurvival analysisHepatologyrecurrencesbusiness.industryLiver Neoplasmshepatocellular carcinomaHepatologymedicine.diseaseHepatitis Chepatocellular carcinoma; prognosis; recurrences; survival; Hepatology030220 oncology & carcinogenesisMeta-analysisHepatocellular carcinoma030211 gastroenterology & hepatologyprognosisNeoplasm Recurrence LocalbusinessAdjuvantprognosi
researchProduct

NUPR1 works against the metabolic stress-induced autophagy-associated cell death in pancreatic cancer cells.

2013

The incidence of pancreatic adenocarcinoma is increasing with more than 43,000 predicted new cases in the US and 65,000 in Europe this year. Pancreatic cancer patients have a short life expectancy with less than 3–4% 5-y survival, which results in an equivalent incidence and mortality rate. One of the major challenges in pancreatic cancer is the identification of pharmacological approaches that overcome the resistance of this cancer to therapy. Intensive research in the past decades has led to the classification of pancreatic cancers and the identification of the driver key genetic events. Despite the advances in understanding the molecular mechanisms responsible for pancreatic cancer patho…

Oncologymedicine.medical_specialtyCell SurvivalDrug resistanceDiseaseBiologyProtein Serine-Threonine KinasesModels BiologicalAurora KinasesStress PhysiologicalPancreatic cancerInternal medicineCarcinomamedicineAutophagyBasic Helix-Loop-Helix Transcription FactorsHumansMolecular BiologyCell DeathMechanism (biology)Mortality rateCancerCell Biologymedicine.diseaseAutophagic PunctumNeoplasm ProteinsEndocrinologyDrug Resistance NeoplasmAdenocarcinomaCarcinoma Pancreatic DuctalAutophagy
researchProduct

Orbital rhabdomyosarcoma in childhood

1997

Background: Rhabdomyosarcoma is the most common malignant orbital tumor in children. Treatment modalities (individualized therapy or study protocol) have been changed radically. Surgery was supplemented by radiation therapy and chemotherapy. The objective of our retrospective analysis was to define the prognosis in correlation to changes of treatment in an unselected patient group of a single institution. Patients and methods: Between 1954 and 1995, 18 patients (age at presentation 1 month to 17 years, 11 male and 7 females) with orbital rhabdomyosarcoma were diagnosed and treated at our institution. Results: The 5-year survival rate was 76 %. Primary exenteration was replaced by tumor rese…

Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentMicrosurgerymedicine.diseasePrimary tumorSurgeryRadiation therapyOphthalmologyEl NiñoInternal medicinemedicineSarcomabusinessRhabdomyosarcomaSurvival rateDer Ophthalmologe
researchProduct

First results for resetting the antitumor immune response by immune corrective surgery in colon cancer.

1998

BACKGROUND: A critical step for cancer recurrence is the failure of the cellular immune response. It is suspected that chronic humoral immune responses against some tumor-associated antigens (TAA) can contribute to that failure. METHODS: In this study, we tested the ability of an immune corrective surgical procedure to prevent recurrences of colon cancer in stages I, II, and III. Radiolabeled anti-TAG antibodies injected intravenously become concentrated on TAG-72 immune complexes presented by follicular dendritic cells, which are responsible for the persistent humoral response against TAG-72 TAA. Using a hand-held gamma probe, we can intraoperatively detect and remove lymph nodes involved …

Oncologymedicine.medical_specialtyColorectal cancerAntibodies NeoplasmImmune systemAntigenAntigens NeoplasmInternal medicineCarcinomamedicineHumansProspective StudiesLymph nodeNeoplasm StagingAntigen PresentationbiologyFollicular dendritic cellsbusiness.industryGeneral Medicinemedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureTreatment OutcomeRadioimmunodetectionImmunologyAntibody FormationColonic Neoplasmsbiology.proteinLymph Node ExcisionSurgeryLymphImmunotherapyLymph NodesAntibodyNeoplasm Recurrence LocalbusinessAmerican journal of surgery
researchProduct

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.

2010

Oncologymedicine.medical_specialtyColorectal cancerDisease-Free SurvivalAdvanced colorectal cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicCetuximabbusiness.industryIncidenceCancerAntibodies MonoclonalHematologymedicine.diseaseChemotherapy regimenOxaliplatinCarcinoembryonic AntigenIrinotecanClinical PracticeEuropeTreatment OutcomeOncologybusinessColorectal Neoplasmsmedicine.drugFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct